Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
Autolus Therapeutics plc (AUTL) will announce its Q4 and full year 2023 results on March 14, 2024. The company will host a conference call to discuss financial results and business updates.
02/29/2024 - 07:00 AM
LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it will release its fourth quarter and full year 2023 results and operational highlights on Thursday March 14, 2024.
Management will host a conference call and webcast at 8:30 am EDT/12:30 pm GMT to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
Contact:
Olivia Mansero.manser@autolus.com
Julia Wilsonj.wilson@autolus.com
Susan A. Noonansusan@sanoonan.com
When will Autolus Therapeutics plc release its Q4 and full year 2023 results?
Autolus Therapeutics plc will release its fourth quarter and full year 2023 results on Thursday, March 14, 2024.
What type of therapies does Autolus Therapeutics plc develop?
Autolus Therapeutics plc develops next-generation programmed T cell therapies.
How can one access the conference call hosted by Autolus Therapeutics plc?
Conference call participants should pre-register using the provided link to receive dial-in numbers and a personal PIN to access the call.
Who can be contacted for more information about Autolus Therapeutics plc?
For more information about Autolus Therapeutics plc, you can contact Olivia Manser at +44 (0) 7780 471 568 or Julia Wilson at +44 (0) 7818 430877.
What is the ticker symbol for Autolus Therapeutics plc?
The ticker symbol for Autolus Therapeutics plc is AUTL.
AUTL Rankings
#2489 Ranked by Stock Gains
AUTL Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
United Kingdom
City
58 Wood Lane
About AUTL
autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a leading biotechnology company focussed on the development and commercialisation of engineered t-cell therapies for haematological and solid tumours. autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient’s own cells.
